KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Raw Materials (2017 - 2021)

Aquestive Therapeutics (AQST) has 4 years of Raw Materials data on record, last reported at $833000.0 in Q1 2021.

  • For Q1 2021, Raw Materials fell 35.18% year-over-year to $833000.0; the TTM value through Mar 2021 reached $833000.0, down 35.18%, while the annual FY2020 figure was $789000.0, 36.58% down from the prior year.
  • Raw Materials reached $833000.0 in Q1 2021 per AQST's latest filing, up from $789000.0 in the prior quarter.
  • Across five years, Raw Materials topped out at $1.4 million in Q1 2019 and bottomed at $729000.0 in Q2 2018.
  • Average Raw Materials over 4 years is $1.1 million, with a median of $1.2 million recorded in 2020.
  • Peak YoY movement for Raw Materials: surged 71.06% in 2019, then tumbled 36.58% in 2020.
  • A 4-year view of Raw Materials shows it stood at $1.3 million in 2018, then fell by 3.04% to $1.2 million in 2019, then plummeted by 36.58% to $789000.0 in 2020, then rose by 5.58% to $833000.0 in 2021.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $833000.0 in Q1 2021, $789000.0 in Q4 2020, and $1.2 million in Q3 2020.